SAVIENT PHARMACEUTICALS INC Financial Statements (2026 and earlier)
Company Profile
| Business Address |
ONE TOWER CENTER EAST BRUNSWICK, NJ 08816 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2833 - Medicinal Chemicals and Botanical Products (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2013 MRQ | 12/31/2012 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 96,281 | |||
| Cash and cash equivalent | 50,332 | |||
| Short-term investments | 45,949 | |||
| Receivables | 4,341 | |||
| Inventory, net of allowances, customer advances and progress billings | ✕ | 4,325 | ||
| Inventory | 4,325 | |||
| Prepaid expense and other current assets | ✕ | 4,367 | ||
| Total current assets: | 109,314 | |||
| Noncurrent Assets | ||||
| Property, plant and equipment | 2,050 | |||
| Regulated entity, other noncurrent assets | 5,800 | |||
| Restricted cash and investments | 2,873 | |||
| Deferred costs | 4,969 | |||
| Other undisclosed noncurrent assets | (5,800) | |||
| Total noncurrent assets: | 9,892 | |||
| TOTAL ASSETS: | 119,206 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 6,585 | |||
| Interest and dividends payable | 3,150 | |||
| Accounts payable | 3,435 | |||
| Debt | 60 | |||
| Other liabilities | 21,516 | |||
| Deferred revenue and credits | 580 | |||
| Other undisclosed current liabilities | 2,875 | |||
| Total current liabilities: | 31,616 | |||
| Noncurrent Liabilities | ||||
| Long-term debt and lease obligation, including: | 223,087 | |||
| Long-term debt, excluding current maturities | 222,914 | |||
| Capital lease obligations | 233 | |||
| Other undisclosed long-term debt and lease obligation | (60) | |||
| Liabilities, other than long-term debt | 2,973 | |||
| Other liabilities | 2,973 | |||
| Total noncurrent liabilities: | 226,060 | |||
| Total liabilities: | 257,676 | |||
| Equity | ||||
| Equity, attributable to parent | (138,297) | |||
| Common stock | 731 | |||
| Additional paid in capital | 397,191 | |||
| Accumulated other comprehensive loss | (304) | |||
| Accumulated deficit | (535,915) | |||
| Total equity: | (138,297) | |||
| Other undisclosed liabilities and equity | (173) | |||
| TOTAL LIABILITIES AND EQUITY: | 119,206 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2013 TTM | 12/31/2012 | ||
|---|---|---|---|
| Revenues (Revenue, Net) | 18,023 | ||
| Cost of revenue (Cost of Product and Service Sold) | (22,382) | ||
| Gross profit: | (4,359) | ||
| Operating expenses | (137,121) | ||
| Other undisclosed operating income | 22,382 | ||
| Operating loss: | (119,098) | ||
| Nonoperating income | 203 | ||
| Investment income, nonoperating | 164 | ||
| Gain, foreign currency transaction, before tax | 64 | ||
| Other nonoperating income | 2,714 | ||
| Interest and debt expense | (2,092) | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 2,675 | ||
| Loss from continuing operations: | (118,312) | ||
| Loss before gain (loss) on sale of properties: | (118,312) | ||
| Net loss available to common stockholders, diluted: | (118,312) | ||
Comprehensive Income ($ in thousands)
| 9/30/2013 TTM | 12/31/2012 | ||
|---|---|---|---|
| Net loss: | (118,312) | ||
| Other comprehensive loss | (319) | ||
| Comprehensive loss, net of tax, attributable to parent: | (118,631) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.